HLA-A2 expression, stage, and survival in colorectal cancer

International Journal of Colorectal Disease

Volumn 23, Issue 8, 2008, Pages 767-772

  Kiewe, Philipp ^a   Mansmann, Veit ^a   Scheibenbogen, Carmen ^a   Buhr, Heinz Johannes ^a   Thiel, Eckhard ^a   Nagorsen, Dirk ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MICROMET AG   (Germany)

Author keywords

Colorectal cancer; HLA; HLA A2; Immunization; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; HLA A2 ANTIGEN; HLA ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SEROLOGY; SEX DIFFERENCE; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ADULT; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HLA-A2 ANTIGEN; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 45449098050     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-008-0488-y     Document Type: Article

References (23)

1. Provenzano M, Panelli MC, Mocellin S, Bracci L, Sais G, Stroncek DF, Spagnoli GC, Marincola FM (2006) MHC-peptide specificity and T-cell epitope mapping: Where immunotherapy starts. Trends Mol Med 12:465-472
2. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357
3. Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U (2003) Rational peptide-based tumour vaccine development and T cell monitoring. Semin Cancer Biol 13:423-429
4. Nagorsen D, Thiel E (2006) Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12:3064-3069
5. Mosolits S, Ullenhag G, Mellstedt H (2005) Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 16:847-862
6. Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S (2005) Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23:7536-7545
7. Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE (2005) Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 11:7470-7479
8. Kubler K, Arndt PF, Wardelmann F, Krebs D, Kuhn W, van der Ven K (2006) HLA-class II haplotype associations with ovarian cancer. Int J Cancer 119:2980-2985
9. Montova L, Saiz I, Rey G, Vela F, Clerici-Larradet N (1998) Cervical carcinoma: Human papillomavirus infection and HLA-associated risk factors in the Spanish population. Eur J Immunogenet 25:329-337
10. Eivazi-Ziaei J, Dastgiri S, Majidi J, Vaez J, Asvadi I, Mahmoudpour A (2006) Human leukocyte antigen and esophageal cancer in the northwestern region of Iran. Dis Esophagus 19:238-240
11. Planelles D, Nagore E, Moret A, Botella-Estrada R, Vila E, Guillen C, Montoro JA (2006) HLA class II polymorphisms in Spanish melanoma patients: Homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br J Dermatol 154:261-266
12. Fensterle J, Trefzer U, Berger T, Andersen MH, Ugurel S, Becker JC (2006) HLA-B8 association with late-stage melanoma - an immunological lesson? BMC Med 4:5
13. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV (2006) Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 103:145-150
14. Magnusson PKE, Enroth H, Eriksson I, Held M, Nyren O, Engstrand L, Hansson LE, Gyllensten UB (2001) Gastric cancer and human leukocyte antigen: Distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori. Cancer Res 61:2684-2689
15. Ohmori M, Yasunaga S, Maehara Y, Sugimachi K, Sasazuki T (1997) DNA typing of HLA class I (HLA-A) and class II genes (HLA-DR, -DQ and -DP) in Japanese patients with gastric cancer. Tissue Antigens 50:277-282
16. Li Z, Chen D, Zhang C, Li Y, Cao B, Ning T, Zhao Y, You W, Ke Y (2005) HLA polymorphisms are associated with Helicobacter pylori infected gastric cancer in a high risk population, China. Immunogenetics 56:781-787
17. Lovig T, Andersen SN, Thorstensen L, Diep CB, Meling GI, Lothe RA, Rognum TO (2002) Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer 87:756-762
18. Yun HR, Lee WY, Lee OS, Cho YB, Yun SH, Chun HK (2007) The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status. Int J Colorectal Dis 22:1301-1310
19. Ju JH, Chang SC, Wang HS, Yang SH, Jiang JK, Chen WC, Lin TC, Hung Hsu, Wang FM, Lin JK (2007) Changes in disease pattern and treatment outcome of colorectal cancer: A review of 5,474 cases in 20 years. Int J Colorectal Dis 22:855-862
20. McArdle CS, McMillan DC, Hole DJ (2003) Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 90:711-715
21. Wichmann MW, Müller C, Hornung HM, Lau-Werner U, Schildberg FW, Colorectal Cancer Study Group (2001) Gender differences in long-term survival of patients with colorectal cancer. Br J Surg 88:1092-1098
22. Verschueren RC, Mulder NH, Van Loon AJ, De Ruiter AJ, Szabo BG (1997) The anatomical substrate for a difference in surgical approach to rectal cancer in male and female patients. Anticancer Res 17:637-641
23. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, Mack SJ, Chen IH, Hsu MM, Yang CS, Brinton LA, Levine PH, Erlich HA (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94:1780-1789